6:19 PM
 | 
Apr 07, 2010
 |  BC Extra  |  Top Story

FDA panel votes against Daxas approval

FDA's Pulmonary-Allergy Drugs Advisory Committee voted 10-5 on Wednesday that safety and efficacy data do not provide substantial evidence to support the approval of Daxas roflumilast from Forest Laboratories Inc. (NYSE:FRX) and Nycomed (Zurich, Switzerland) for chronic obstructive pulmonary disease (COPD). The negative vote came after two...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >